Akkeri

Biotechnology Research • • 11-20 Employees

Company overview

Headquarters	XX
Website	akkeri.com
NAICS	541714
Keywords	Gene Therapy, Medical Writing, Consulting, Ophthalmology, Risk Assessment, Cell Therapy, Vaccines, Toxicology, Reproductive Toxicology, Good Laboratory Practices, Fda Meetings, Nonclinical, Regulatory Strategies, Nonclinical Consulting, Nonclinical Drug Development, Ind/Nda/Bla, Nonclinical Safety Strategies, Nonclinical Study Monitoring, Permissible Daily Exposure Calculation, Pharmacokinetics/Toxicokinetic, Preclinical Abuse Liability
Founded	2023
Employees	11-20

Key Contact at Akkeri

Juliana Cave

Founder/ Cfo & Coo

Akkeri Email Formats

Akkeri uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@akkeri.com), used 66.7% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@akkeri.com	66.7%
{first name}{last name}	johndoe@akkeri.com	33.3%

About Akkeri

Akkeri is a consulting group specializing in nonclinical drug development. We provide experienced strategic advice and operational support on drug development programs to include program design, regulatory guidance, scientific & regulatory writing (IND, NDA, CTA, MAA, IB, pre-IND), due diligence, nonclinical study planning, management & monitoring, and project team participation. We have experience across modalities such as small molecules, biologics, cell & gene therapy, and vaccines for a range of therapeutic areas and routes of administration. Our consultants bring a wealth of industry experience from biotech, large pharma, CROs, and FDA. We value a strong working relationship with clients and look forward to an opportunity to partner with your team!

Akkeri revenue & valuation

Annual revenue	$941,105
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$3,100,000
Total funding	No funding